Author:
Arévalo Ruales K.,Elkes B.,Miehle N.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Adams TN, Zhang D, Batra K, Fitzgerald JE (2018) Pulmonary manifestations of large, medium, and variable vessel vasculitis. Respir Med 145:182–191. https://doi.org/10.1016/j.rmed.2018.11.003
2. Cid M, Unizony S, Pupim L, Fang F, Pirrello J, Ren A, Samant M, Zhou TPJ (2020) Mavrilimumab (anti GM-CSF receptor α monoclonal antibody) reduces time to flare and increases sustained remission in a phase 2 trial of patients with giant cell Arteritis [abstract. Arthritis Rheumatol 72(suppl). https://acrabstracts.org/abstract/mavrilimumab-anti-gm-csf-receptor-%ce%b1-monoclonal-antibody-reduces-time-to-flare-and-increases-sustained-remission-in-a-phase-2-trial-of-patients-with-giant-cell-arteritis/
3. Hellmich B, Agueda A, Monti S et al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases 2020(79):19–30. https://doi.org/10.1136/annrheumdis-2019-215672
4. Hoffman GS, Cid MC, Hellmann DB et al (2002) A multicenter , randomized , double-blind , placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309–1318. https://doi.org/10.1002/art.10262
5. Hunder GG, Bloch DA, Michel BA et al (2010) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128. https://doi.org/10.1002/art.1780330810
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献